JPH0551280B2 - - Google Patents
Info
- Publication number
- JPH0551280B2 JPH0551280B2 JP59112519A JP11251984A JPH0551280B2 JP H0551280 B2 JPH0551280 B2 JP H0551280B2 JP 59112519 A JP59112519 A JP 59112519A JP 11251984 A JP11251984 A JP 11251984A JP H0551280 B2 JPH0551280 B2 JP H0551280B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- polynucleotide
- stranded
- measured
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000040430 polynucleotide Human genes 0.000 claims description 52
- 108091033319 polynucleotide Proteins 0.000 claims description 52
- 239000002157 polynucleotide Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 40
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 description 33
- 102000053602 DNA Human genes 0.000 description 33
- 239000000243 solution Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N βâMercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- -1 succinimide ester Chemical class 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 101710183568 Serine/threonine-protein kinase PknK Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical class ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- RNIPJYFZGXJSDD-UHFFFAOYSA-N 2,4,5-triphenyl-1h-imidazole Chemical compound C1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 RNIPJYFZGXJSDD-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- QVIKUAVXSRNDPS-UHFFFAOYSA-N 2-methoxynaphthalen-1-ol Chemical compound C1=CC=CC2=C(O)C(OC)=CC=C21 QVIKUAVXSRNDPS-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- LZGUHMNOBNWABZ-UHFFFAOYSA-N n-nitro-n-phenylnitramide Chemical compound [O-][N+](=O)N([N+]([O-])=O)C1=CC=CC=C1 LZGUHMNOBNWABZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
ïŒç£æ¥äžã®å©çšåéïŒ
ç¹å®ã®æ§é ãæããããªãã·ãªãæ žé
žïŒDNAïŒ
ãããã¯ãªãæ žé
žïŒRNAïŒã®æž¬å®ã¯çååŠåé
ã«ãããŠéèŠã§ãããäŸãã°äººè¡æž
äžã®DNAã
枬å®ããããšã«ãã€ãŠãŠã€ã«ã¹ææã®æ€æ»ããã
ã¯éºäŒæ§çŸæ£ã®çºèŠãªã©ãè¡ãªãããšãã§ããã
æ¬çºæã¯ãã®ãããªDNAåã³RNAã®ç¹å®ã®ãã®
ã簡䟿ãã€æ£ç¢ºã«æž¬å®ãããæ¹æ³ãæäŸãããã®
ã§ããã
ïŒåŸæ¥ã®æè¡åã³çºæã解決ããããšããåé¡
ç¹ïŒ
åŸæ¥ããã®DNAåã³RNAã®æž¬å®æ¹æ³ãšããŠ
ã¯ãè©Šæãå€æ§åŠçããŠåŸãäžæ¬éDNAïŒïŒ³â
DNAïŒåã¯äžæ¬éRNAïŒïŒ³âRNAïŒãåºçžã«çµ
åããããã®åºçžã«ã©ãžãªã¢ã€ãœããŒããæšèã
ãâDNAåã¯ïŒ³âRNAãäœçšãããŠåºçžã®ïŒ³
âDNAåã¯ïŒ³âRNAãšãã€ããªããã圢æãã
ãŠããæªåå¿ã®æšèâDNAåã¯ïŒ³âRNAãé€
å»ããåºçžã®æŸå°ç·ã枬å®ããæ¹æ³ãè¡ãªãããŠ
ããããã®æ¹æ³ã¯æž¬å®ã®éã«åºå®åãæŽæµçæ°å€
ãã®å·¥çšãå¿
èŠãšããç¹ã«è©Šæã®åºå®åã«é·æé
ãèŠãããšããããæäœã®åŽååã³æéã®äž¡æ¹ã«
åé¡ããã€ãã
ãŸãã枬å®å¯Ÿè±¡ã§ããäžæ¬éããªãã¯ã¬ãªãã
ãšãã€ããªããããäžæ¬éããªãã¯ã¬ãªããã®20
å¡©åºãã150å¡©åºããšã«é
µçŽ ãããªãã³ãããã
ã³çã®æšèç©ãçµåããããã®æšèç©ãå©çšããŠ
枬å®ããæ¹æ³ãç¥ãããŠãããããããªãããã
ããã®æ¹æ³ã¯æšèç©ã®éãå¢ãããšãã€ããªãã
ããDNAãžã®ç¹ç°æ§ãäœäžããäžæ¹ãæšèç©ã®
éãæžå°ããããšæž¬å®æ床ãäœäžãããšããåé¡
ç¹ããã€ãã
ãã®ã»ããæè¿DNAãããŒããçããåæã
ãŠãã®5â²ç«¯åã³3â²ç«¯ã«æšèç©ãçµåãããæè¡ã
éçºããããïŒç¹éæ58â40099å·å
¬å ±ïŒããã®æ¹
æ³ãDNAãããŒããçããããç¹ç°æ§ãäœãã
ãŸããæšèç©ã®éãå°ãªãããæ床ãå
åã§ãªã
ãšããåé¡ããã€ãã
ïŒåé¡ç¹ã解決ããããã®æ段ïŒ
æ¬çºæã¯ããããã®åé¡ç¹ã解決ããããªãã¯
ã¬ãªããã®æž¬å®æ¹æ³ãæäŸãããã®ã§ããã枬å®
察象ã®äžæ¬éããªãã¯ã¬ãªãããšãã€ããªããã
圢æããäžæ¬éããªãã¯ã¬ãªããã®5â²ç«¯ãããã¯
3â²ç«¯ã«ç¹å®ã®é«ååååç©ãéžæçã«çµåããã
ãšãã€ããªããã圢æããç¹ç°æ§ãæãªãããã
ãŸããã®é«ååååç©ã«å€æ°ã®æšèç©ãçµåãã
ãããšã«ãããã®ãã€ããªãããé«æ床ã§æž¬å®ã§
ããããšãèŠåºããŠãªããããã®ã§ããã
ããªãã¡ãæ¬çºæã¯ã枬å®å¯Ÿè±¡ã§ããäžæ¬éã
ãªãã¯ã¬ãªãããšäºæ¬éããªãã¯ã¬ãªããã圢æ
ãããäžæ¬éããªãã¯ã¬ãªããã§ãã€ãŠãããªã
ããããããªãµãã«ã©ã€ããããªãªã³é
žãããªãš
ãã¬ã³ã°ãªã³ãŒã«åã³ããªããã«ã¢ã«ã³ãŒã«ãã
æã矀ããéžæãããã€æšèç©ãæããé«ååå
åç©ããã®5â²ç«¯åã¯3â²ç«¯ã«éžæçã«çµåãããã
ãªãã¯ã¬ãªãããã枬å®å¯Ÿè±¡ã§ããäžæ¬éããªã
ã¯ã¬ãªãããšæ¥è§Šãããããšãç¹åŸŽãšããããªã
ã¯ã¬ãªããã®æž¬å®æ¹æ³ã«é¢ãããã®ã§ããã
枬å®å¯Ÿè±¡ã¯äžæ¬éããªãã¯ã¬ãªããïŒä»¥äžã枬
å®å¯Ÿè±¡ããªãã¯ã¬ãªãããšãããïŒã§ããã枬å®
察象ããªãã¯ã¬ãªããã«ã¯DNAåã³RNAãå«
ããè©Šæäžã«å«ãŸããããªãã¯ã¬ãªãããäºæ¬é
ã§ããå Žåã«ã¯æ°Žé
žåãããªãŠã 溶液ã®æ·»å ãªã©
ã®ã¢ã«ã«ãªåŠçãããã¯ç±åŠçãªã©ã«ããäžæ¬é
ã«ããŠããå¿
èŠããããè©Šæã®çš®é¡ã¯åããªã
ããäŸãã°äººè¡æž
ãå°¿ãçµç¹æœåºç©ãªã©ã§ããã
人è¡æž
ãªã©ã®ããã«ããªãã¯ã¬ãªãããèçœãšçµ
åããŠããããããããå Žåã«ã¯è©Šæããããã¢
ãŒãŒçã§åŠçããŠèçœãåé¢ããŠããã®ãããã
ãã®æž¬å®å¯Ÿè±¡ããªãã¯ã¬ãªãããšæ¥è§Šãããäž
æ¬éããªãã¯ã¬ãªããïŒä»¥äžãæšèããªãã¯ã¬ãª
ãããšãããïŒã¯æšèç©ãæããé«ååååç©ã
5â²ç«¯åã¯3â²ç«¯ã«çµåãããã€è©²æž¬å®å¯Ÿè±¡äžæ¬éã
ãªãã¯ã¬ãªãããšäºæ¬éããªãã¯ã¬ãªããã圢æ
ããããã®ã§ããã
ãã®äžæ¬éããªãã¯ã¬ãªããã¯çŸåšç¥ãããŠã
ãåºçžããªãã¯ã¬ãªããåææ³ãããã¯ãã©ã¹ã
ãããçšããéºäŒåå·¥åŠã«ããγâDNAæ³ãªã©
ã«ããåæããããšãã§ããããŸããäžè¬ã®çå
åŠçææ³ã«ããDNAãæœåºãããããã¢ã«ã«ãª
ã§å€æ§ãããŠãŠäžæ¬éã«ããããšãã§ããããã®
ã»ããæ¢ã«åžè²©ãããŠãããã®ãå©çšããããšã
ã§ããã
容æã«å€éã«äžæ¬éã®ããªãã¯ã¬ãªãããå
¥æ
ã§ããç¹ã§éºäŒåå·¥åŠçææ³ãå©çšããããšã¯å¥œ
ãŸãããäŸãã°ãmp7ãã¢ãŒãžã«ç®çã®DNAã
å°å
¥ãããããÏÃ174ã«å°å
¥ããŠå¹é€ãããšå®¹
æã«éç¶ã®äžæ¬éDNAãåŸãããšãã§ãããåŸ
ãããäžæ¬éDNAã¯ããèªèº«ã§äºæ¬éã«ãªãã
ãšããªãã®ã§éåžžã®äžæ§ãã€åžžæž©äžã§ä¿åã§ã
ãããã®ãããããªãã¯ã¬ãªããåæåŸã«äžæ¬é
ã«å€ããåŠçãäžèŠã«ãªããäœåãªæéãçç¥ã§
ããã
é«ååååç©ã¯ã氎溶æ§ã§ãããã€æž¬å®å¯Ÿè±¡ã
ãªãã¯ã¬ãªãããšéç¹ç°åå¿ããªããã®ã§ããã°
ãããååéã¯1000以äžã®ãã®ã奜ãŸãããé«å
åååç©ã®äŸãšããŠã¯ããŒã©ãã³ããã¢ã·ã¢ã
ã³ãããšãªãã³çã®ããªãããããå¯æº¶æ§ããã¹
ãã©ã³ãã«ã«ããã·ã¡ãã«åããã¹ãã©ã³ãã¢ã
ãåããã¹ãã©ã³ãã¢ãããŒã¹çã®ããªãµãã«ã©
ã€ããããªãªã³é
žãããªãšãã¬ã³ã°ãªã³ãŒã«åã³
ããªããã«ã¢ã«ã³ãŒã«ãæããããšãã§ãããã
ããã¯ãäŸãã°æšèç©ã®å°å
¥ã容æã«ããããã«
ã¢ããåºãã«ã«ããã·ã«åºãããªãŒã«åºãæ°Žé
ž
åºãåå¿æ§ã¯ãã«åºãªã©ãäºãå°å
¥ããŠãããŠã
ããã
äžæ¬éããªãã¯ã¬ãªããã®ç«¯éšã®ãã¡ãäžè¬ç
ã¯3â²ç«¯ã®é«ååååç©ãçµåãããã»ãã容æã§
ããããŸãããã®ããªãã¯ã¬ãªãããžã®åœ±é¿ãå°
ãªãã
3â²ç«¯ãžçµåãããæ¹æ³ãšããŠã¯ãäŸãã°ïŒ³âã¢
ã»ãã«ããã·ã«ã¢ããã¢ããã·ã³ãžãã¹ããšãŒã
ã«äžæ¬éããªãã¯ã¬ãªãããå ããããã«RNA
T4ãªã¬ãŒãŒãäœçšããããš3â²ç«¯ã«ïŒ³âã¢ã»ãã«
åºãå°å
¥ããããããã«æ°Žé
žåãããªãŠã 氎溶液
ãäœçšããããšã¢ã»ãã«åºãé€å»ãããŠSHåºã«
ãªããããã«ãã¬ã€ããåºãå°å
¥ãã氎溶æ§ãŒã©
ãã³ãäœçšãããã°ãäžæ¬éããªãã¯ã¬ãªããã®
3â²ç«¯ã«ãŒã©ãã³ãå°å
¥ããããšãã§ãããRNA
T4ãªã¬ãŒãŒãå©çšããããšã«ããã3â²ç«¯ã«ã¢ã
ãåºãããã¯ã«ã«ããã·ã«åºãªã©ã容æã«å°å
¥ã§
ããã®ã§ãããããå©çšããŠé«ååååç©ãçµå
ãããããšãã§ããããããã®å®èœåºãå©çšããŠ
é«ååååç©ãçµåãããæ¹æ³ã¯ãäŸãã°
âMethod in Immunology and
ImmunochemistryâïŒC.A.Williams et alãïŒ
1976ïŒAcademic Press N.Y.ïŒãšããé
µçŽ å
ç«
枬å®æ³ãïŒç³å·ããå»åŠæžé¢ã1978幎ïŒãªã©ã®æ
æžã«èšèŒãããŠããæ¹æ³ã®ãªãããé©å®éžæããŠ
å©çšããããšãã§ãããäŸãã°ã¢ããåºçžäºéã
çµåãããå Žåã«ã¯ããžã€ãœã·ã¢ããŒãæ³ãã°ã«
ã¿ã«ã¢ã«ãããæ³ããžãã«ãªããã³ãŒã³æ³ããã³
ãŸããã³æ³çãå©çšããããšãã§ãããŸããã¢ã
ãåºãšã«ã«ããã·ã«åºãšã®éãçµåãããå Žåã«
ã¯ãã«ã«ããã·ã«åºããµã¯ã·ã³ã€ãããšã¹ãã«å
ããæ¹æ³ã®ã»ãã«ã«ããžã€ããæ³ããŠããã¯ãŒã
è©Šè¬æ³çãå©çšããããšãã§ãããã¢ããåºãšç³
éãæ¶æ©ããéãšãŠçŽ é
žé
žåæ³ïŒNakaneæ³ïŒã
ãããããªãŒã«åºãå©çšããå Žåã«ã¯ãäŸãã°ã
ãäžæ¹ã®åŽã®ã«ã«ããã·ã«åºããµã¯ã·ã³ã€ãããš
ã¹ãã«åããŠããã«ã·ã¹ãã€ã³ãåå¿ãããŠããª
ãŒã«åºãå°å
¥ããããªãŒã«åºåå¿æ§äºäŸ¡æ¶æ©è©Šè¬
ãçšããŠåæ¹ãçµåããããšãã§ãããããšãã«
åºãå©çšããæ¹æ³ãšããŠã¯ãžã¢ãŸåæ³ãã¢ã«ãã«
åæ³ãªã©ãããã
3â²ç«¯ã«çµåãããæ¹æ³ãšããŠã¯ãäžèšã®æ¹æ³ä»¥
å€ã«ãäŸãã°äºã3â²ç«¯ã«äžèšã®æ¹æ³ã§é«åååå
ç©ãçµåãããŠããããã¯ã¬ãªãããçšããŠäžæ¬
éããªãã¯ã¬ãªãããåºçžåæããæåŸã«åºçžéš
åããé«ååååç©ãåãé¢ãæ¹æ³ãããã
äžæ¹ã5â²ç«¯ã«çµåãããå Žåã«ã¯ãäŸãã°äºæ¬
éDNAç¶æ
ã«ãããŠDNA T4ãªã¬ãŒãŒãäœçšã
ããŠäºãã¢ããåºãã«ã«ããã·ã«åºçãçµåãã
ãŠããã修食DNAã5â²ç«¯ã«çµåããããã®åŸäž
æ¬éDNAã«åé¢ããã°5â²ç«¯ã«ã¢ããåºãã«ã«ã
ãã·ã«åºçãå°å
¥ããããšãã§ãããããã§ãã
ã®å®èœåºãå©çšããŠäžèšã®æ¹æ³ã«ããé«åååå
ç©ãçµåãããã°ããã
é«ååååç©ã¯3â²ç«¯åã³5â²ç«¯ã®äž¡æ¹ã«å°å
¥ããŠ
ãããããšã¯ãããŸã§ããªãã
æšèç©ã®çš®é¡ã¯ç¹ã«éå®ããããã®ã§ã¯ãªãã
é
µçŽ ãããã¹ãã€ãã¯ã°ã«ãŒããããªãã³ãã¢ã
ãžã³ããããã³ãè¢å
ç©è³ªãååŠçºå
ç©è³ªãæŸå°
æ§åäœå
çŽ ãªã©ãåºãå©çšã§ããããããã¯æž¬å®
æ¹æ³ãç°¡åã§ãã€é«ååååç©ãžã®çµåã容æãª
ãã®ãæãŸããã
é
µçŽ ã®äŸãšããŠã¯ãã°ã«ã³ãŒã¹âïŒâãªã³é
žè±
æ°ŽçŽ é
µçŽ ããããœãããŒãŒãαâã¢ãã©ãŒãŒãã
ã¬ãŒãããããã²ããŒãŒãã¢ã«ã«ãªæ§ãã¹ãã¢ã¿
ãŒãŒããã«ãªãã·ããŒãŒãβâã¬ã©ã¯ãã·ããŒ
ãŒãã¯ã¬ã¢ãã³ãããŒãŒããªããã¯ã¬ã¢ãŒãŒãã
ãã·ãªããŒãŒãªã©ãæããããšãã§ãããé
µçŽ ã¯
ç¹ç°æ§ãé«ããç¹ã§èç±æ§ã®ãã®ã奜ãŸããã
ããã¹ãã€ãã¯ã°ã«ãŒãã®äŸãšããŠã¯ãFADã
NADHãNADPH2ãã¢ãããããªã³é
žãããªã
ããµãŒã«ãªã³é
žãADPãATPãªã©ãæããããš
ãã§ããã
ããªãã³ã¯ã¢ããžã³ãçµåãããèªå°äœã§ãã€
ãŠãããã
ã¢ããžã³ã¯ããªãã³ãšçµåããããã®ã§ããã
ã¹ãã¬ããã¢ããžã³ãããã¯ãããã®èªå°äœã§ã
ã€ãŠãããã
ãããã³ã¯äŸãã°ãžãããããšããŒã«ããžãã
ãã¢ããªã³ãªã©ã§ããã
è¢å
ç©è³ªã¯ããã«ãªã¬ã»ã€ã³ãããŒããã³ãã
ã³ã·ã«ã¯ãã©ã€ãããã«ãªã¬ã¹ã¯ã¢ãã³ãã¯ããª
ã³ãã¢ã¯ãªãžã³ããã³ãŸãªããµãžã¢ãŸãŒã«ãããª
ã¢ãªãŒã«ã¡ã¿ã³ããã¬ã³é¡ãªã©ã§ããã
ååŠçºå
ç©è³ªã¯ãã«ãããŒã«ãã€ãœã«ãããŒ
ã«ãã¢ã¯ãªãžããŠã ãããããã«ãªãã·ãããã«
ãã€ãªã³ãã€ã³ãã¬ã³âïŒâã€ã«ããããã«ãªã
ã·ããïŒïŒïŒïŒïŒâããªããšãã«ã€ãããŸãŒã«ã
ã«ã·ããšãªã³âã«ã·ããšã©ãŒãŒãªã©ã§ããã
æŸå°æ§åäœå
çŽ ã«ã¯32Pã3Hã35Sã14Cã125Iãªã©
ãå©çšããã°ããã
ãããã®ãªãã§ç¹ã«é
µçŽ ãããã¹ãã€ãã¯ã°ã«
ãŒããããªãã³åã³ãã®èªå°äœäžŠã³ã«ã¢ããžã³ã
ã¹ãã¬ããã¢ããžã³åã³ãããã®èªå°äœã䜿çšã®
簡䟿ããæ床çã®ç¹ã§å¥œãŸããã
æšèç©ã®é«ååååç©ãžã®çµåæ¹æ³ã¯åè¿°ã®é«
ååååç©ãäžæ¬éããªãã¯ã¬ãªããã«çµåãã
ãæ¹æ³ã®ãªãããé©å®éžæããã°ããã
æšèç©ã®é«ååååç©ãžã®çµåéã¯å€ãã»ãã
æãŸããã
ãã®ãããªæšèããªãã¯ã¬ãªããã枬å®å¯Ÿè±¡ã
ãªãã¯ã¬ãªãããšæ¥è§ŠãããŠäºæ¬éããªãã¯ã¬ãª
ããã圢æããããæ¥è§Šãããæ¹æ³ãšããŠã¯ããŸ
ã枬å®å¯Ÿè±¡ããªãã¯ã¬ãªãããå«æãã溶液ã«ã
ããã»ã«ããŒã¹ãã€ã«ã¿ãŒã浞ããŠæž¬å®å¯Ÿè±¡ããª
ãã¯ã¬ãªãããåžçããããããå
åã«æŽæµã
ãã次ã«ããã®ãããã»ã«ããŒã¹ãã€ã«ã¿ãŒãæš
èããªãã¯ã¬ãªãããå«ã溶液ã«æµžæŒ¬ããŠåå¿ã
ãããåå¿æ¡ä»¶ã¯ãããã»ã«ããŒã¹ãã€ã«ã¿ãŒã«
åžçãããŠãã枬å®å¯Ÿè±¡ããªãã¯ã¬ãªãããæšè
ããªãã¯ã¬ãªãããšå
åã«åå¿ããŠãã€ããªãã
ã圢æãããçšåºŠãããããã®æ¡ä»¶ã¯æšèããªã
ã¯ã¬ãªããã®æ¿åºŠçã«ããããéåžžã¯20ã75âã
PHïŒãïŒçšåºŠã§0.5ã48æéçšåºŠã§ããã
åå¿çµäºåŸã¯ãã®ãã€ã«ã¿ãŒãå
åã«æŽæµãã
ãã€ã«ã¿ãŒã«åžçãããæšèç©ã枬å®ããã枬å®
æ¹æ³ã¯æšèç©ã®çš®é¡ã«å¿ããŠåã
ã®å
¬ç¥ã®æ¹æ³ã«
åŸã€ãŠè¡ãªãã°ããã
ïŒäœçšïŒ
æ¬çºæã®æ¹æ³ã«ãããŠã¯ãæšèããªãã¯ã¬ãªã
ãã枬å®å¯Ÿè±¡ããªãã¯ã¬ãªããã«å¯Ÿãç¹ç°çã«ã
ã€ããªããã圢æããããããŠããã®ãã€ããªã
ãã圢æããæšèããªãã¯ã¬ãªããã®æšèç©ã®é
ã枬å®ããããšã«ãã枬å®å¯Ÿè±¡ããªãã¯ã¬ãªãã
ã®éãæ±ããããšãã§ããã
ïŒçºæã®å¹æïŒ
æ¬çºæã®æ¹æ³ã«ãããŠã¯ãæšèããªãã¯ã¬ãªã
ãã®ç«¯éšä»¥å€ã«ã¯æšèç©ãçµåãããŠããªããšã
ããã枬å®å¯Ÿè±¡ããªãã¯ã¬ãªãããšãã€ããªãã
ã圢æããç¹ç°æ§ãæãªãããªãããŸããæšèç©
ãé«ååååç©ã«çµåãããŠãããšããããæšè
ç©ã®éãå€ãããããšãã§ãããã®çµæã枬å®æ
床ãé«ããããšãã§ãããæ¬çºæã®æ¹æ³ã¯æäœã
ç°¡åã§ãããšããå©ç¹ãæããã
ïŒå®æœäŸïŒ
å®æœäŸ ïŒ
(1) HBVâDNAãããŒãã®èª¿è£œ
500mlã®æ
¢æ§ïŒ¢åèçæ£è
ã®ããŒã«è¡æž
ã
9000rpmã§15åéé å¿ããåŸãããäžæž
ãïŒâ
100000Ãïœã§ïŒæéè¶
é å¿ããŠHBVç²åããã¬
ãããšããŠéããããã®ãã¬ããã0.1M NaClã
1mM EDTAã0.1ïŒ
ïŒâã¡ã«ã«ãããšã¿ããŒã«
åã³0.1ïŒ
BSAãå«ã0.01Mããªã¹âå¡©é
žç·©è¡æ¶²
ïŒPH7.5ïŒ10mlã«æº¶ããããã®ãŠã€ã«ã¹æº¶æ¶²ã®ãã¡
ïŒmlãä¿åããæ®ïŒmlã100000Ãïœã§å床ïŒæé
è¶
é å¿ããŠãã¬ãããåŸãã
ãã®ãã¬ããã0.5ïŒ
NPâ40ãå«ã10mMããª
ã¹âå¡©é
žã0.1M NaClPH7.5溶液200ÎŒã§åŠç
ããDNAããªã¡ã©ãŒãŒã掻æ§åããããã®æº¶æ¶²
ã«1mM dATPã1mM dTTPã2.5ÎŒM dGTPã
2.5ÎŒM dCTPãå«ã0.08M MgCl20.2Mããªã¹ç·©
è¡æ¶²ïŒPH7.5ïŒ50ÎŒãå ããŠïŒæéå æž©ãããã
ã®æº¶æ¶²ã30ïŒ
ã·ãŠãŒã¯ããŒã¹æº¶æ¶²ã®å
¥ã€ãé å¿ã
ãŠãŒãã«éå±€ããSW65ããŒã¿ãŒïŒããã¯ãã³ç€Ÿ
補ïŒãçšã50000rpmã§ïŒæéé å¿ããŠãã¬ãã
ãåŸãããã®ãã¬ãããããããŒãŒã§åŠçããåŸ
ããã溶液ãããšããŒã«ã§ïŒåæœåºåŠçãããæœ
åºæ¶²ãïŒã20ïŒ
ã·ãŠãŒã¯ããŒã¹ã°ã©ãžãšã³ãã§
50000rpmã«ãŠïŒæéé å¿ããŠ15S DNAåç»ãé
ããããããŒã«ããããã®åç»ãã15S DNAã
ãšã¿ããŒã«ãçšããŠæ²æŸ±ããã也ç¥ããŠç®çã®
HBVâDNAãåŸãã
(2) ããã¯ãã©ã³ã¹ã¬ãŒã·ãšã³ã«ããDNAãã
ãŒãã®èª¿è£œ
5mM MgCl2ã10mM2âã¡ã«ã«ãããšã¿ããŒ
ã«ã5ÎŒM dTTPã5ÎŒM dGTPã5ÎŒM dCTPå
ã³5ÎŒM dATPãå«ã50mMããªã¹âHClç·©è¡æ¶²
ïŒPH7.5ïŒ100ÎŒã«åé
ã§åŸãããHBVâDNA1ÎŒ
ïœãDNase  100pïœåã³DNAããªã¡ã©ãŒãŒ
 100pïœãå ããŠ15âã§90åéã€ã³ããŠããŒ
ãããããã®æº¶æ¶²ãããšããŒã«ã§æœåºãã
Sephadex â50ã«ã©ã ã§ç²Ÿè£œããŠHBVâDNA
ãåŸãã
(3) é«ååååç©åã³æšèç©ã®çµå
ãã®ããã«ããŠåŸãäºæ¬éHBVâDNAã
0.5Næ°Žé
žåãããªãŠã 溶液ã§åé¢ãããŠäžæ¬é
DNAãšãããã®æº¶æ¶²ãäžåãããããã«çŽã¡ã«
ã¢ããããã·ã«ã¢ããã·ã³ãžãã¹ããšãŒããå
ãã次ã«RNAãªã¬ãŒãŒ10Uãå ãããïŒæéå
å¿åŸãåå¿æ¶²ãã²ã«éããŠã¢ããåHBVâäž
æ¬éDNAãåŸãã
次ã«ãããã«ååé50000ã®CHMåãŒã©ãã³
ïŒmgãå ããããã«æ°Žæº¶æ§ã«ã«ããžã€ããïŒmgã
å ããŠ37âã§ïŒæéPH5.0ã«ä¿æããããã®åå¿
液ãã»ãã¢ã¯ãªã«ïŒ³â300ã«ã©ã ã§ã²ã«éãã
CHMåãŒã©ãã³çµåHBVâäžæ¬éDNAãåŸãã
ãã®CHMåãŒã©ãã³çµåHBVâäžæ¬éDNA
ã«åžžæ³ã«ãã€ãŠåŸãSHåãã«ãªãã·ããŒãŒ10mg
ãå ããPH7.0ãïŒâã§äžå€æªæãããåå¿ç©ã
ã»ãã¢ããŒã¹4Bã§ã²ã«éããŠæªåå¿ã®ãã«ãª
ãã·ããŒãŒãé€å»ããç®çã®æšèäžæ¬éDNAã
åŸãã
(4) ããªãã¯ã¬ãªããã®æž¬å®
HBãŠã€ã«ã¹æ§èçæ£è
è¡æž
100ÎŒã«0.5N
NaOH100ÎŒãå ããŠå®€æž©ã§10åéæªæããã
次ã«ã0.5N HCl100ÎŒãå ããããã«200ÎŒïœïŒ
mlã®ãããã€ã³ãããŒãŒïŒ«æº¶æ¶²200ÎŒãå ããŠ
70âã§ïŒæéåå¿ããããããããã飜åããšã
ãŒã«âã¯ãããã«ã 氎溶液ïŒïŒïŒïŒïŒ200ÎŒã
å ããåå±€ããæ°Žå±€200ÎŒããããã»ã«ããŒã¹
ãåºã«æ·ãã96ãŠãšã«ã®ãã€ã¯ããã¬ãŒãã«å
¥ã
ããåãŠãšã«ã®æ°Žå±€ãåžåŒéåŸ85âã§ïŒæéã€
ã³ããŠããŒãããPBSã§ïŒåæŽæµãããããã«
åé
ã§åŸãããæšèäžæ¬éDNA1ÎŒïœãå«ã溶液
200ÎŒãå ãã40âã§18æéå æž©ããããã®ã
ã€ã«ã¿ãŒã0.1Mé
¢é
žâ10ÎŒM EDTAâ1M NaCl
PH7.0ã§ïŒåæŽæµåŸããã®ãã€ã«ã¿ãŒã«0.5mM4â
ã¡ããã·ããããŒã«åã³2mMH2O2ãå«ãåºè³ªæº¶
液PH7.0 100ÎŒãå ããŠ30åéåå¿ããããåã
ã€ã«ã¿ãŒã«çºè²ããã¹ãããããªãã©ã¯ãã¡ãŒã¿
ãŒã§æž¬å®ããè¡æž
åžéçãšçžå¯Ÿåå¿åŒ·åºŠã®é¢ä¿ã
æ±ããçµæã第ïŒå³ã«ç€ºãã
åçš®è¡æž
ã®HBVâDNAã®éãäžèšã®æ¹æ³ã«ã
ã€ãŠæž¬å®ããåŸæ¥æ³ã§ããã©ãžãªã¢ã€ãœããŒãæš
èåºçžæ³ã«ãã枬å®å€ãšæ¯èŒããçµæãäžè¡šã«ç€º
ãã
(Industrial application field) Deoxyribonucleic acid (DNA) with a specific structure
Alternatively, the measurement of ribonucleic acid (RNA) is important in the field of biochemistry; for example, by measuring DNA in human serum, it is possible to test for viral infection or discover genetic diseases.
The present invention provides a method for easily and accurately measuring such specific DNA and RNA. (Problems to be Solved by the Prior Art and the Invention) Conventionally, as a method for measuring DNA and RNA, single-stranded DNA (S-
DNA) or single-stranded RNA (S-RNA) is bound to a solid phase, and S-DNA or S-RNA labeled with a radioisotope is applied to the solid phase to
- A method has been used in which a hybrid is formed with DNA or S-RNA, unreacted labeled S-DNA or S-RNA is removed, and radiation on a solid phase is measured. This method requires many steps such as fixation and washing during measurement, and in particular, it takes a long time to fix the sample, which poses problems in terms of both operational labor and time. In addition, 20% of the single-stranded polynucleotide that hybridizes with the single-stranded polynucleotide to be measured is
A method is also known in which a label such as an enzyme, biotin, or hapten is bound to every 150 bases, and this label is used for measurement. However, these methods have a problem in that increasing the amount of labeled material reduces specificity for hybrid DNA, while decreasing the amount of labeled material reduces measurement sensitivity. In addition, a technique has recently been developed in which a DNA probe is cut short and a label is attached to its 5' and 3' ends (Japanese Patent Application Laid-open No. 1983-40099), but this method also requires that the DNA probe is short. Therefore, specificity is low;
In addition, there was a problem that the sensitivity was not sufficient because the amount of labeled substance was small. (Means for Solving the Problems) The present invention provides a method for measuring polynucleotides that solves these problems. 5â² end of nucleotide or
By selectively binding a specific polymer compound to the 3â² end, the specificity of forming a hybrid is not impaired, and
The present invention was also made based on the discovery that this hybrid can be measured with high sensitivity by binding a large number of labels to this polymer compound. That is, the present invention provides a single-stranded polynucleotide capable of forming a double-stranded polynucleotide with a single-stranded polynucleotide to be measured, which is composed of a polypeptide, a polysaccharide, a polyphosphoric acid, a polyethylene glycol, and a polyvinyl alcohol. A polynucleotide selected from the group consisting of: a polymer compound having a label selectively bound to its 5' end or 3' end is brought into contact with a single-stranded polynucleotide to be measured. This invention relates to a method for measuring polynucleotides. The measurement target is a single-stranded polynucleotide (hereinafter referred to as the measurement target polynucleotide). Polynucleotides to be measured include DNA and RNA. If the polynucleotide contained in the sample is double-stranded, it is necessary to make it single-stranded by an alkali treatment such as addition of a sodium hydroxide solution or heat treatment. The type of sample does not matter, but examples include human serum, urine, and tissue extracts.
If there is a possibility that polynucleotides may be bound to proteins, such as in human serum, it is preferable to separate the proteins by treating the sample with protease or the like. The single-stranded polynucleotide (hereinafter referred to as labeled polynucleotide) that is brought into contact with this polynucleotide to be measured is a polymeric compound having a labeled substance.
It is bound to the 5' end or 3' end and can form a double-stranded polynucleotide with the single-stranded polynucleotide to be measured. This single-stranded polynucleotide can be synthesized by the currently known solid-phase polynucleotide synthesis method or the γ-DNA method using genetic engineering using a plasmid. It is also possible to extract DNA using general biochemical methods and denature it with alkali to make it into a single strand. In addition, those already commercially available can also be used. It is preferable to use genetic engineering techniques because single-stranded polynucleotides can be easily obtained in large quantities. For example, single-stranded DNA can be easily obtained by introducing the desired DNA into mp7 phage and culturing it into ÏÃ174 cells. The single-stranded DNA obtained does not become double-stranded by itself, so it can be stored at normal neutral temperatures and at room temperature. Therefore, there is no need for a process to convert the polynucleotide into a single strand after synthesis, and extra effort can be omitted. The polymer compound may be one that is water-soluble and does not non-specifically react with the polynucleotide to be measured. The molecular weight is preferably 1000 or more. Examples of polymeric compounds include polypeptides such as gelatin, hemocyanin, and ferritin, soluble dextran, carboxymethylated dextran, aminated dextran, polysaccharides such as amylose, polyphosphoric acid, polyethylene glycol, and polyvinyl alcohol. . For example, an amino group, a carboxyl group, a thiol group, a hydroxyl group, a reactive chlorine group, etc. may be introduced into these in advance in order to facilitate the introduction of a label. Of the ends of a single-stranded polynucleotide, it is generally easier to bind a polymer compound to the 3' end, and this polynucleotide is less affected. For example, a single-stranded polynucleotide is added to S-acetylhexylaminoadenosine diphosphate, and RNA is attached to the 3' end.
When T4 ligase is applied, an S-acetyl group is introduced at the 3' end. When this is treated with an aqueous sodium hydroxide solution, the acetyl group is removed and becomes an SH group. If water-soluble gelatin into which a maleimide group has been introduced is applied to this, single-stranded polynucleotides can be formed.
Gelatin can be introduced at the 3â² end. RNA
By using T4 ligase, an amino group or a carboxyl group can be easily introduced at the 3' end, so it is also possible to use these to bond a polymer compound. Methods for bonding macromolecular compounds using these functional groups are described, for example, in âMethod in Immunology and
âImmunochemistryâ (CA Williams et al,
The methods described in books such as "Enzyme Immunoassay" (Ishikawa et al., Igaku Shoin, 1978) can be selected and used as appropriate. For example, when bonding between amino groups, the diisocyanate method, glutaraldehyde method, difluorobenzene method, benzoquinone method, etc. can be used, and when bonding between amino groups and carboxyl groups, In addition to the method of converting a carboxyl group into a succinimide ester, a carbodiimide method, a Woodward reagent method, etc. can be used. There is also a periodate oxidation method (Nakane method) that crosslinks amino groups and sugar chains. When using a thiol group, for example, the carboxyl group on the other side is esterified with succinimide, this is reacted with cysteine to introduce a thiol group, and the two are bonded using a thiol group-reactive divalent cross-linking reagent. can do. Methods that utilize phenyl groups include diazotization and alkylation. In addition to the method described above, methods for binding to the 3' end include, for example, solid-phase synthesis of a single-stranded polynucleotide using a nucleotide to which a polymer compound has been previously bound to the 3' end by the method described above. Finally, there is also a method of separating the polymer compound from the solid phase part. On the other hand, when binding to the 5' end, for example, in a double-stranded DNA state, modified DNA to which amino groups, carboxyl groups, etc. have been bound in advance by the action of DNA T4 ligase is linked to the 5' end, and then If the DNA is separated into single-stranded DNA, amino groups, carboxyl groups, etc. can be introduced at the 5' end. Therefore, a polymer compound may be bonded using this functional group by the method described above. It goes without saying that the polymer compound may be introduced at both the 3' end and the 5' end. The type of sign is not particularly limited,
Enzymes, prosthetic groups, biotin, avidin, haptens, fluorophores, chemiluminescent substances, radioisotopes, etc. can be widely used. It is desirable that these substances can be easily measured and easily bonded to a polymer compound. Examples of enzymes include glucose-6-phosphate dehydrogenase, hexokinase, α-amylase, malate dehydrogenase, alkaline phosphatase, peroxidase, β-galactosidase, creatine kinase, ribonuclease, penicillinase, and the like. The enzyme is preferably thermostable in order to increase specificity. Examples of prosthetic groups include FAD,
Examples include NADH, NADPH 2 , aminopyrophosphate, pyridoxal phosphate, ADP, and ATP. Biotin may be a derivative capable of binding avidin. Avidin can bind to biotin,
It may be streptavidin or a derivative thereof. Haptens include, for example, dinitrophenol, dinitroaniline, and the like. Fluorescent substances include fluorescein, rhodamine, dansyl chloride, fluorescamine, coumarin, acridine, benzoxadiazole, triarylmethane, and pyrenes. Chemiluminescent substances include luminol, isoluminol, acridinium, hydroperoxide, porphyrin, intren-3-yl hydroperoxide, 2,4,5-triphenylimidazole,
Such as luciferin-luciferase. 32 P, 3 H, 35 S, 14 C, 125 I, etc. may be used as radioactive isotopes. Among these, enzymes, prosthetic groups, biotin and its derivatives, avidin,
Streptavidin and derivatives thereof are preferred in terms of ease of use, sensitivity, etc. The method for binding the label to the polymer compound may be appropriately selected from among the methods described above for binding the polymer compound to the single-stranded polynucleotide. It is desirable that the amount of the label bound to the polymer compound be large. Such a labeled polynucleotide is brought into contact with a polynucleotide to be measured to form a double-stranded polynucleotide. As for the contacting method, first, a nitrocellulose filter is immersed in a solution containing the polynucleotide to be measured to adsorb the polynucleotide to be measured, and then thoroughly washed. Next, this nitrocellulose filter is immersed in a solution containing the labeled polynucleotide and allowed to react. The reaction conditions are preferably such that the polynucleotide to be measured adsorbed on the nitrocellulose filter sufficiently reacts with the labeled polynucleotide to form a hybrid. These conditions depend on the concentration of the labeled polynucleotide, etc., but are usually 20-75°C.
It takes about 0.5 to 48 hours at a pH of about 5 to 9. After the reaction is complete, wash this filter thoroughly.
Measure the label adsorbed on the filter. The measurement method may be carried out according to each known method depending on the type of label. (Function) In the method of the present invention, the labeled polynucleotide specifically forms a hybrid with the polynucleotide to be measured. Then, by measuring the amount of the labeled polynucleotide that has formed this hybrid, the amount of the polynucleotide to be measured can be determined. (Effects of the Invention) In the method of the present invention, the specificity of forming a hybrid with a polynucleotide to be measured is not impaired since no label is bound to any part other than the end of the labeled polynucleotide. Furthermore, since the label is bound to the polymer compound, the amount of the label can be increased, and as a result, the measurement sensitivity can be increased. The method of the invention also has the advantage of being simple to operate. (Example) Example 1 (1) Preparation of HBV-DNA probe 500 ml of pooled serum from chronic hepatitis B patients was
Centrifuge at 9000 rpm for 15 minutes and store the resulting supernatant at 4°C.
The HBV particles were collected as a pellet by ultracentrifugation at 100,000 xg for 5 hours. This pellet was mixed with 0.1M NaCl,
Dissolve in 10 ml of 0.01 M Tris-HCl buffer (PH7.5) containing 1 mM EDTA, 0.1% 2-mercaptoethanol, and 0.1% BSA, save 5 ml of this virus solution, and incubate the remaining 5 ml again at 100,000 à g for 5 ml. A pellet was obtained by ultracentrifugation for an hour. This pellet was treated with 200 µ of a 10 mM Tris-HCl, 0.1M NaClPH7.5 solution containing 0.5% NP-40 to activate DNA polymerase. This solution contains 1mM dATP, 1mM dTTP, 2.5ΌM dGTP,
50Ό of 0.08M MgCl 2 0.2M Tris buffer (PH7.5) containing 2.5ΌM dCTP was added and heated for 3 hours. This solution was layered on a centrifuge tube containing a 30% sucrose solution, and centrifuged for 3 hours at 50,000 rpm using an SW65 rotor (manufactured by Beckman) to obtain a pellet. This pellet was treated with pronase, and the resulting solution was extracted twice with phenol. Prepare the extract using a 5-20% sucrose gradient.
The 15S DNA fraction was collected by centrifugation at 50,000 rpm for 3 hours and pooled. From this fraction, 15S DNA is precipitated with ethanol and dried to obtain the desired
HBV-DNA was obtained. (2) Preparation of DNA probe by Nikk translation Add the sample obtained in the previous section to 100Ό of 50mM Tris-HCl buffer (PH7.5) containing 5mM MgCl 2 , 10mM 2-mercaptoethanol, 5ΌM dTTP, 5ΌM dGTP, 5ΌM dCTP and 5ΌM dATP. HBV-DNA1Ό
g, 100 pg of DNase I and 100 pg of DNA polymerase I were added and incubated at 15°C for 90 minutes. This solution was extracted with phenol,
HBV-DNA was purified using a Sephadex G-50 column.
I got it. (3) Binding of a polymer compound and a label The double-stranded HBV-DNA thus obtained is
Separate into single strands with 0.5N sodium hydroxide solution
This solution was neutralized as DNA. To this was immediately added aminohexyladenosine diphosphate, followed by 10 U of RNA ligase. After 1 hour of reaction, the reaction solution was gel-filtered to obtain aminated HBV-single-stranded DNA. Next, 1 mg of CHM gelatin having a molecular weight of 50,000 was added thereto, and further 1 mg of water-soluble carbodiimide was added thereto, and the mixture was maintained at pH 5.0 at 37° C. for 1 hour. This reaction solution was gel-filtered through a Sephacryl S-300 column,
CHM-formed gelatin-bound HBV-single-stranded DNA was obtained. This CHM-formed gelatin-bound HBV-single-stranded DNA
10mg of SH peroxidase obtained by conventional method
was added, and the mixture was stirred overnight at pH 7.0 and 4°C. The reaction product was gel-filtered with Sepharose 4B to remove unreacted peroxidase, and the desired labeled single-stranded DNA was obtained. (4) Measurement of polynucleotide: 0.5N in 100Ό of HB viral hepatitis patient serum
100Ό of NaOH was added and stirred at room temperature for 10 minutes.
Next, add 100Ό of 0.5N HCl and add 200Όg/
Add 200 ÎŒl of protein kinase K solution
The reaction was carried out at 70°C for 1 hour. Then, 200Ό of a saturated phenol-chloroform aqueous solution (1:1) was added, and 200Ό of the separated aqueous layer was placed in a 96-well microplate lined with nitrocellulose at the bottom. The aqueous layer of each well was filtered by suction, incubated at 85° C. for 1 hour, and washed once with PBS. Add to this a solution containing 1 Όg of labeled single-stranded DNA obtained in the previous section.
200Ό was added and heated at 40°C for 18 hours. This filter was mixed with 0.1M acetic acid - 10ΌM EDTA - 1M NaCl.
After washing 4 times with PH7.0, add 0.5mM4â to this filter.
100Ό of a substrate solution PH7.0 containing methoxynaphthol and 2mMH 2 O 2 was added and reacted for 30 minutes. The colored spots on each filter were measured using a refractometer, and the relationship between serum dilution rate and relative reaction intensity was determined. The results are shown in FIG. The amount of HBV-DNA in various serums was measured by the above method, and the results were compared with the values measured by the conventional radioisotope labeling solid phase method, and the results are shown in the table below.
ãè¡šã
å®æœäŸ ïŒ
å®æœäŸïŒã§äœè£œããäºæ¬éHBVâDNA1mg
ïŒïŒmlïŒãšHBVâDNAãå°ããäžæ¬éM13âã
ã¢ãŒãžDNA5mgïŒïŒmlïŒã«ãã«ã ã¢ããïŒmlãå
ããïŒåéãã®æ··å液ã沞ãšããããã次ã«ãã
ãã«ïŒmlã®ç·©è¡æ¶²ïŒ0.07ã¢ã«ïŒ ããªã¹â
HCl2ã¢ã«ïŒ NaClã15mM EDTAPH7.5ïŒã
å ãã50âã§ïŒæéãããŠããã«60âã§ïŒæéå
æž©ããã
ãã®åå¿æ¶²ãBioâGel A50ïœã§ã²ã«éãã
ãã€ããªããããDNAãšæªåå¿ã®DNAãåé¢ã
ãããã€ãåç»ã®è¿ãã«æº¶åºãããæåã®ããŒã¯
ãåç»ããããã«NaClã0.1Mã«ãªãããã«ç²æ«
ãå ããŠæº¶ãããããããŠãããã«100ïŒ
ãšã¿ã
ãŒã«ã溶液ïŒmlã«å¯ŸãïŒåã®æ¯çïŒïŒmlïŒã§å
ããâ70âã§ïŒæéæŸçœ®ããã次ã«ã17000Ãïœã§
10åéé å¿ãããšã¿ããŒã«æ²æ®¿ç©ã50mlã®0.1N
NaOHã0.25mM EDTAã0.001ïŒ
ããšããŒã«ã¬
ããã§æº¶è§£ããããã ã¡ã«ãããBioâGelA50
ã§ã²ã«éããç®çã®äžæ¬éHBVâDNAãåŸ
ãã
ãã®äžæ¬éDNAã«ïŒâã¢ã»ãã«ã¡ã«ã«ãã
ããã·ã«ã¢ããã·ã³ãžãã¹ããšãŒãïŒ10mMïŒå
ã³RNAãªã¬ãŒãŒ10Uãå ãã10mMããªã¹â
HClã1mM EDTAã0.1M NaClPH7.3ã§37âã§
ïŒæéåå¿ãããããããBioã²ã«A60ã§ã²ã«
éãã修食äžæ¬éDNAåç»ãååãããPEGâ
15000ã§ïŒmlã«æ¿çž®åŸã0.1N NaOHã§PH1.0ã«ç¶
æãå®å
šã«ã¢ã»ãã«åºãé€å»ãããSPDâåã«
ãããŒã«çµåããã¹ãã©ã³10mgãPH7.0ã§å ãã
ïŒâã§äžå€æŸçœ®ããã
次ã«ãããããã€ãªã²ã«A60ã§ã²ã«éããç®
çã®ã«ãããŒã«çµåæšèHBVâäžæ¬éDNAãåŸ
ãã
HBãŠã€ã«ã¹æ§èçæ£è
è¡æž
100ÎŒã«0.5N
NaOH100ÎŒãå ããŠå®€æž©ã§10åéæªæããã
次ã«ã0.5N HCl100ÎŒãå ããããã«200ÎŒïœïŒ
mlã®ãããã€ã³ãããŒãŒïŒ«æº¶æ¶²200ÎŒãå ããŠ
70âã§ïŒæéåå¿ããããããããã飜åããšã
ãŒã«âã¯ãããã«ã 氎溶液ïŒïŒïŒïŒïŒ200ÎŒã
å ããåå±€ããæ°Žå±€200ÎŒããããã»ã«ããŒã¹
ãåºã«æ·ãã96ãŠãšã«ã®ãã€ã¯ããã¬ãŒãã«å
¥ã
ããåãŠãšã«ã®æ°Žå±€ãåžåŒéåŸ85âã§ïŒæéã€
ã³ããŠããŒããPBSã§ïŒåæŽæµãããããã«å
é
ã§åŸãããæšèäžæ¬éDNA100mgãå«ã溶液
200ÎŒãå ãã65âã§18æéå æž©ããããã®ã
ã€ã«ã¿ãŒã0.1Mé
¢é
žâ10ÎŒM EDTAâ1M NaCl
PH7.0ã§ïŒåæŽæµåŸããã®ãã€ã«ã¿ãåããšãã
ã«ããããã¡ãŒã¿ãŒäžã§H2O22mMãPOD10Uã
Na2CO30.1MPH9.5ã200ÎŒå«ãçºå
管ã«ç§»ãã
çºå
匷床ã枬å®ããã
åŸãããçµæã第ïŒå³ã«ç€ºãã[Table] Example 2 1 mg of double-stranded HBV-DNA prepared in Example 1
(1 ml) and 5 mg (2 ml) of single-stranded M13-phage DNA containing HBV-DNA were added with 8 ml of formamide, and the mixture was boiled for 5 minutes. Next, add 2 ml of buffer (0.07 mol/Tris-
2 mol of HCl/NaCl, 15mM EDTAPH7.5) was added, and the mixture was heated at 50°C for 4 hours and further heated at 60°C for 1 hour. This reaction solution was gel-filtered with Bio-Gel A50m,
Hybridized DNA and unreacted DNA were separated. The first peak eluted near the void fraction was fractionated, and powder was added to it to make NaCl 0.1M and dissolved. Further, 100% ethanol was added at twice the ratio (2 ml) per 1 ml of the solution, and the mixture was left at -70°C for 2 hours. Next, at 17000Ãg
Centrifuge for 10 minutes and precipitate with 50ml 0.1N ethanol.
Dissolved in NaOH, 0.25mM EDTA, 0.001% phenol. Immediately apply this to Bio-GelA50
The target single-stranded HBV-DNA was obtained by gel filtration. 6-S acetylmercaptohexyladenosine diphosphate (10mM) and 10U of RNA ligase were added to this single-stranded DNA, and 10mM Tris-
The mixture was reacted with HCl, 1mM EDTA, and 0.1M NaClPH7.3 at 37°C for 2 hours. This was gel-filtered with Biogel A60, and a modified single-stranded DNA fraction was collected. PEGâ
After concentrating to 2 ml at 15,000, the pH was maintained at 1.0 with 0.1N NaOH to completely remove acetyl groups. Add 10 mg of SPD-modified luminol-conjugated dextran at pH 7.0,
It was left at 4°C overnight. Next, this was gel-filtered through Biogel A60 to obtain the desired luminol-conjugated labeled HBV-single-stranded DNA. 0.5N in 100Ό of HB viral hepatitis patient serum
100Ό of NaOH was added and stirred at room temperature for 10 minutes.
Next, add 100Ό of 0.5N HCl and add 200Όg/
Add 200 ÎŒl of protein kinase K solution
The reaction was carried out at 70°C for 1 hour. Then, 200Ό of a saturated phenol-chloroform aqueous solution (1:1) was added, and 200Ό of the separated aqueous layer was placed in a 96-well microplate lined with nitrocellulose at the bottom. The aqueous layer of each well was filtered by suction, incubated at 85° C. for 1 hour, and washed once with PBS. Add to this a solution containing 100 mg of labeled single-stranded DNA obtained in the previous section.
200Ό was added and heated at 65°C for 18 hours. This filter was washed with 0.1M acetic acid - 10ΌM EDTA - 1M NaCl.
After washing 4 times at PH7.0, cut out this filter.
H2O2 2mM , POD10U, in a luminophotometer
Transfer Na2CO30.1MPH9.5 to an arc tube containing 200Ό ,
The luminescence intensity was measured. The results obtained are shown in FIG.
å³é¢ã¯ããããHBãŠã€ã«ã¹æ§èçæ£è
è¡æž
ã«
ã€ããŠæ¬çºæã®æ¹æ³ã§æž¬å®ããçµæã瀺ããã®ã§
ããã第ïŒå³ã¯äžå®æœäŸã«ãããè¡æž
åžéçãšçº
è²ã¹ãããã®åå°åŒ·åºŠã®é¢ä¿ãããããŠç¬¬ïŒå³ã¯
ä»ã®å®æœäŸã«ãããè¡æž
åžéçãšååŠçºå
匷床ã®
é¢ä¿ããããã瀺ããŠããã
The drawings all show the results of measuring the serum of patients with HB viral hepatitis using the method of the present invention; Fig. 1 shows the relationship between the serum dilution rate and the reflection intensity of the colored spot in one example, and Fig. 2 shows the relationship between the serum dilution rate and the reflection intensity of the colored spot in one example. shows the relationship between serum dilution rate and chemiluminescence intensity in other Examples.
Claims (1)
æ¬éããªãã¯ã¬ãªããã圢æãããäžæ¬éããªã
ã¯ã¬ãªããã§ãã€ãŠãããªãããããããªãµãã«
ã©ã€ããããªãªã³é žãããªãšãã¬ã³ã°ãªã³ãŒã«å
ã³ããªããã«ã¢ã«ã³ãŒã«ããæã矀ããéžæãã
ãã€æšèç©ãæããé«ååååç©ããã®5â²ç«¯åã¯
3â²ç«¯ã«éžæçã«çµåãããããªãã¯ã¬ãªãããã
枬å®å¯Ÿè±¡ã§ããäžæ¬éããªãã¯ã¬ãªãããšæ¥è§Šã
ããããšãç¹åŸŽãšããããªãã¯ã¬ãªããã®æž¬å®æ¹
æ³ã1. A single-stranded polynucleotide capable of forming a double-stranded polynucleotide with the single-stranded polynucleotide to be measured, selected from the group consisting of polypeptide, polysaccharide, polyphosphoric acid, polyethylene glycol, and polyvinyl alcohol. and the polymeric compound having the label is located at its 5â² end or
A polynucleotide selectively attached to the 3â² end,
A method for measuring polynucleotides, which comprises bringing them into contact with a single-stranded polynucleotide to be measured.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59112519A JPS60256059A (en) | 1984-06-01 | 1984-06-01 | Assay of polynucleotide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59112519A JPS60256059A (en) | 1984-06-01 | 1984-06-01 | Assay of polynucleotide |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60256059A JPS60256059A (en) | 1985-12-17 |
JPH0551280B2 true JPH0551280B2 (en) | 1993-08-02 |
Family
ID=14588674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59112519A Granted JPS60256059A (en) | 1984-06-01 | 1984-06-01 | Assay of polynucleotide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60256059A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082830A (en) * | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5861468A (en) * | 1981-10-09 | 1983-04-12 | Hitachi Ltd | Immunoassay method and immune reagent used for said method |
JPS60144662A (en) * | 1983-12-12 | 1985-07-31 | ã¢ã¬ããŠã©ãŒã»ãã€ã¢ã°ãã¹ãã€ãã¯ã¹ã»ã€ã³ã³ãŒãã¬ãŒããã | Nucleic acid probe, polynucleotide alignment and testing method and reagent group for detecting antibody thereof |
-
1984
- 1984-06-01 JP JP59112519A patent/JPS60256059A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5861468A (en) * | 1981-10-09 | 1983-04-12 | Hitachi Ltd | Immunoassay method and immune reagent used for said method |
JPS60144662A (en) * | 1983-12-12 | 1985-07-31 | ã¢ã¬ããŠã©ãŒã»ãã€ã¢ã°ãã¹ãã€ãã¯ã¹ã»ã€ã³ã³ãŒãã¬ãŒããã | Nucleic acid probe, polynucleotide alignment and testing method and reagent group for detecting antibody thereof |
Also Published As
Publication number | Publication date |
---|---|
JPS60256059A (en) | 1985-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1272443A (en) | Solution-phase dual hybridization assay for detecting polynucleotide sequences | |
JPH0378120B2 (en) | ||
US4968602A (en) | Solution-phase single hybridization assay for detecting polynucleotide sequences | |
EP0379559B1 (en) | Method and reagents for detecting nucleic acid sequences | |
US4724202A (en) | Use of non-hybridizable nucleic acids for the detection of nucleic acid hybridization | |
US4752566A (en) | Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide | |
EP0163220B1 (en) | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies | |
US5053326A (en) | Hybridization method and probe | |
JPH06502766A (en) | Non-isotopic detection of nucleic acids using a polystyrene support-based sandwich hybridization assay and compositions used therefor | |
JPH02309254A (en) | Detection of substance bondable specifically in body liquor and reagent receptor | |
JPS5983056A (en) | Digoxigenine immunogen composite body, antibody, marked composite body, related derivative and reagent system using these substance and immunity test method | |
JPH11511558A (en) | Fluorescent and luminescent label compositions and methods of using them | |
JP3093116B2 (en) | Nucleic acid detection method | |
JP2511221B2 (en) | Method for measuring polymerase activity | |
JP2613203B2 (en) | Solution-phase single-cross assays for detection of polynucleotide sequences | |
EP0146815B1 (en) | Nucleic acid hybridization assay employing antibodies to intercalation complexes | |
JPH0551280B2 (en) | ||
EP0209702A1 (en) | Solid-phase hybridization assay using anti-hybrid antibodies | |
JPH0627740B2 (en) | Antigen measurement method | |
JPH0469345B2 (en) | ||
JPH0515439B2 (en) | ||
JPH0531108B2 (en) | ||
JPH0552199B2 (en) | ||
JPH01101900A (en) | Method and reagent for conducting hybridization | |
EP1098990B1 (en) | Blocked-polymerase polynucleotide immunoassay method and kit |